Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life. - Wikidata - wikimedia - TriplyDB

Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

http://www.wikidata.org/entity/Q34450459

about

Development and Evaluation of a Multiplex Microsphere Assay for Quantitation of IgG and IgA Antibodies against Neisseria meningitidis Serogroup A, C, W, and Y Polysaccharides Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform.The Challenge of Immunoglobulin-G Subclass Deficiency and Specific Polysaccharide Antibody Deficiency--a Dutch Pediatric Cohort Study.Measurement of pneumococcal polysaccharide vaccine responses for immunodeficiency diagnostics: combined IgG responses compared to serotype specific IgG responses.

P2860

Q28397047-80FD7C76-6C95-4A1B-B011-4B9D26DCA132 Q37353525-196A50AF-5665-42FC-9AA5-E13555F45253 Q40804903-2465239F-29AE-4D92-BBC6-A9709FCE02E9 Q45395612-F244DB1C-C328-46CA-8B33-733CDEA15244

P2860

Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

http://www.wikidata.org/entity/Q34450459

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Salivary immune responses to t ...... in the first 2 years of life.

@ast

Salivary immune responses to t ...... in the first 2 years of life.

@en

Salivary immune responses to t ...... in the first 2 years of life.

@nl

type

label

Salivary immune responses to t ...... in the first 2 years of life.

@ast

Salivary immune responses to t ...... in the first 2 years of life.

@en

Salivary immune responses to t ...... in the first 2 years of life.

@nl

prefLabel

Salivary immune responses to t ...... in the first 2 years of life.

@ast

Salivary immune responses to t ...... in the first 2 years of life.

@en

Salivary immune responses to t ...... in the first 2 years of life.

@nl

P1433

Q34450459-DE7AC04E-9D16-49F1-A9F2-5B5889CDEFAC

P1476

Q34450459-EAC3BB5D-9446-4B51-A33D-E23A41E37EB7

P2093

Q34450459-3409666A-F372-4FF6-92AA-1B0662058076

Q34450459-71C11E9D-77F8-4D83-BE9B-741E960F6EF2

Q34450459-7D4195F6-3A5E-4099-A7B7-ADB144FE89F6

Q34450459-960AAD9B-66C3-4202-B2F0-446261E92888

Q34450459-A37FBC0B-1207-420A-A852-30632089F623

Q34450459-C0AB35B8-FE2D-426F-B054-2226C5118D5F

Q34450459-DD56D7B9-767F-4F25-B7C1-25DB41E0FD38

Q34450459-E0CBBD07-47DB-4475-BDDC-5B90C6107243

P2860

Q34450459-0F9FF723-84ED-4AF2-A302-935A8A742FA6

Q34450459-120010F5-86A2-472A-83FF-88156BB8B5CB

Q34450459-1531ACB3-7AD3-473C-A9E7-DE29DFCF79C3

Q34450459-1F9E6F14-B342-4C3C-9541-0E5247316156

Q34450459-25CABBF1-5C18-4C79-B574-8D93318ACC1A

Q34450459-33184580-3263-4980-B0BA-928A715B896F

Q34450459-3C2FE61A-275C-4DB9-B40D-53FE448CE6C2

Q34450459-4D8743E3-89C4-4A5C-B6E3-47E18C81B573

Q34450459-650891E6-DC7D-44A2-B16D-EEA32B22ABA7

Q34450459-73517FDF-A9E1-4224-9FD5-702DD28F2AC4

P304

Q34450459-FD142736-510F-4858-A427-2113420217A9

P31

Q34450459-8B22A533-C132-4D8E-B3DC-ACAF26468BBB

P356

Q34450459-2161FC84-489A-4B1A-916F-F9E0540D7324

P407

Q34450459-4D863CE0-6C06-451A-BBFB-AD2BB36B45C3

P433

Q34450459-5691686C-C7EC-4D6B-81B6-4432F7713C68

P478

Q34450459-B398FB20-DCF6-45DE-BA62-732227571D44

P50

Q34450459-56670BDD-D3C5-44F8-82A7-5E5FB61B2DBB

P577

Q34450459-68AA8257-22D5-4635-992D-0FB669744F39

P5875

Q34450459-6A694DF7-A668-4E2B-9670-B9EC81DA8D8B

P698

Q34450459-D86C213A-750B-49CD-B8C5-58C21F317F43

P932

Q34450459-5BDDC650-10F7-43D7-82FE-76C773E2AEF5

P356

JOURNAL.PONE.0046916

P1433

P1476

Salivary immune responses to t ...... in the first 2 years of life.

@en

P2093

Andries C Bloem

http://www.w3.org/2001/XMLSchema#string

Elisabeth A M Sanders

http://www.w3.org/2001/XMLSchema#string

Elske J M van Gils

http://www.w3.org/2001/XMLSchema#string

Germie P J M van den Dobbelsteen

http://www.w3.org/2001/XMLSchema#string

Gerwin D Rodenburg

http://www.w3.org/2001/XMLSchema#string

Guy A M Berbers

http://www.w3.org/2001/XMLSchema#string

Reinier H Veenhoven

http://www.w3.org/2001/XMLSchema#string

Tomasz Zborowski

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic control of the immunologic response to pneumococcal capsular polysaccharides.

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.

Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae

Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage.

Do salivary antibodies reliably reflect both mucosal and systemic immunity?

Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial.

P304

e46916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0046916

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232281773

http://www.w3.org/2001/XMLSchema#string

P698

23077532

http://www.w3.org/2001/XMLSchema#string

P932

3473066

http://www.w3.org/2001/XMLSchema#string